US biotech researches treatments to reduce muscle loss from blockbuster diet medicines
The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’
Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer
Latest setback for Dato-DXd comes after disappointing results in lung cancer treatment earlier this month
Results offer hope of progress in combating bladder tumours and some forms of breast cancer
High rates of vomiting among those who took strong doses in trials have unsettled investors
Danish pharma company also unveils early data for closely watched oral pill to tackle weight loss
Failure to reach statistical significance sets back effort to build oncology portfolio
Medical breakthroughs come with spiralling price tag, leaving policymakers with tough decisions
A three-part FT series looks at how an influx of money is changing prospects for patients but creating new challenges for healthcare systems
Pandemic winners BioNTech and Moderna face hurdles as they seek to bring their groundbreaking technology to oncology
More trials urged as part of effort to slow cognitive declines with existing medicines
Nice’s ruling on lecanemab demonstrates the lack of readiness to roll out new treatments in the UK
US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound
The first in an FT series looking at the new energy behind the fight for cancer cures
Pharma groups are finally turning their research focus to a huge unmet need
The Food and Drug Administration’s rejection of MDMA-assisted therapy is a missed opportunity
The Swiss company had the first option on a drug that could now become a leading anti-obesity treatment
Pharma companies are moving up the supply chain to secure radioactive materials for a new form of drugs
Maker of Wegovy and Ozempic has 45,000 patients in clinical trials as it seeks to stave off threats from Eli Lilly and Roche
Swiss drugmaker unveils promising data for obesity drug
GSK’s Shingrix is latest drug to show potential for targeting previously untreatable brain disorders
Pharma groups could see almost threefold drop in demand due to US health official decision, says Airfinity
Pharma group seeks to catch up with rivals Eli Lilly and Novo Nordisk in sector projected to be worth $130bn a year
New compound increases strength of antidote for fentanyl and other lethal drugs
